Raymond James Rates Tonix Pharmaceuticals (TNXP) buy
Raymond James maintains its buy rating on Tonix Pharmaceuticals with a $26 price target, a 96.67% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Raymond James rated Tonix Pharmaceuticals Holding Corp. ($TNXP) "buy" with a $26 price target on June 25, 2026.
Since the rating, $TNXP is up 3.0% after 1 week, down 13.4% after 1 month and down 49.6% to date (from the $11.98 close on Jun 25, 2026).
TNXP
Tonix Pharmaceuticals Holding Corp.
Key Points
- Raymond James reiterated its buy rating on Tonix Pharmaceuticals (TNXP) with a target price of $26 on June 25, 2026.
- Raymond James's $26 price target implies 96.67% upside from Tonix Pharmaceuticals Holding Corp.'s ($TNXP) current $13.22 share price.
- Shares of TNXP traded near $12.1 on Thursday, with a market cap of about $194.5 million and a 52-week range of $10.03 to $69.97.
- Insider buying activity includes CEO Seth Lederman purchasing 5,000 shares at $11.79 each on June 9, 2026.
Get $TNXP trade alerts by text
We text you when insiders, Congress or big funds trade $TNXP. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tonix Pharmaceuticals Holding Corp. alert may contain errors. Disclosures
Raymond James reiterated its buy rating on Tonix Pharmaceuticals Holding Corp. (NasdaqGS: TNXP) on June 25, 2026. Analyst Tiago Fauth set a price target of $26 for the company. This follows a period of notable insider buying activity, reflecting a positive outlook.
Raymond James vs. the S&P 500
Hypothetical returns from Raymond James's disclosed trades, not real profit or advice. How we model this.
Tonix Pharmaceuticals Holding Corp. Stock Up 21.6%
Shares of Tonix Pharmaceuticals traded near $12.1 on Thursday. The company has a market cap of approximately $194.5 million. Tonix operates in the biotechnology industry, focusing on therapies for central nervous system disorders and other areas. The stock's 52-week range is between $10.03 and $69.97, and it has a beta of 1.679, indicating higher volatility compared to the market.
$TNXP price target
Tonix Pharmaceuticals Holding Corp. daily closes and this analyst's $26 target. Not advice.
Insider Buying and Selling at Tonix Pharmaceuticals Holding Corp.
Recent insider transactions at Tonix Pharmaceuticals show a series of purchases. On June 12, 2026, Carolyn Taylor bought 1,415 shares at $10.55 each. Earlier, on June 9, 2026, CEO Dr. Seth Lederman acquired 5,000 shares at an average price of $11.79. Richard Newcomb Stillwell also bought 5,000 shares on June 8, 2026, at $11.65 each. These transactions suggest confidence in the company's future.
Analysts Set New Price Targets
On June 25, 2026, Raymond James reiterated its buy rating with a $26 price target. Previously, on May 4, 2026, TD Cowen initiated coverage with a buy rating and a $22 target. The overall analyst consensus for Tonix Pharmaceuticals is a strong buy, with an average target price of $46.25 from four analyst opinions.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company based in Berkeley Heights, New Jersey. It develops and commercializes therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Founded in 2007, the company is led by CEO Dr. Seth Lederman and employs around 142 people. Tonix is working on a range of treatments, including those for fibromyalgia, migraines, and various autoimmune and infectious diseases.
Bottom Line
Raymond James's reiteration of its buy rating with a $26 target highlights confidence in Tonix Pharmaceuticals' potential. The stock's recent trading activity and insider purchases suggest positive sentiment around the company's prospects. Investors often track such developments to gauge market sentiment, though it's worth noting that analyst ratings and insider activity are just parts of the broader investment picture.
Related Filing Alerts
Source: Raymond James's rating change on $TNXP (Jun 25, 2026). Written by software, not financial advice. How we make alerts